Skip to content

Mannkind MNKD Equity Method Investments

Equity Method Investments at other companies

Eli Lilly logo
Eli LillyLLY
$3.12B-3.3%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$56.49M
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's equity method investments?
Mannkind (MNKD) reported equity method investments of $5.01M in Q4 2025.
How has Mannkind's equity method investments changed year-over-year?
Mannkind's equity method investments decreased by 8.6% year-over-year, from $5.48M to $5.01M.
What is the long-term trend for Mannkind's equity method investments?
Over 4 years (2021 to 2025), Mannkind's equity method investments has grown at a -45.5% compound annual growth rate (CAGR), from $56.62M to $5.01M.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.